Biotechnology · Nasdaq

BIIBBiogen Inc.

Last close
$253.40 +1.2%
52-week range
$160.36 to $261.00
Market cap
$37.5B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$9.89B
+2% vs FY24
Net income
$1.29B
-21% vs FY24
Free cash flow
$2.05B
-25% vs FY24
Net cash
-$2.47B
Cash $3.82B, debt $6.29B

Stock price

-12% since Dec 2016

Valuation vs its own 10 years

Above its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
108x
7.8x108x
Highest point in its range, above its median of 17.0x
Price / sales
3.6x
1.8x5.6x
52nd percentile, above its median of 3.4x
EV / EBITDA
26.6x
5.9x26.6x
Highest point in its range, above its median of 9.8x
Price / free cash flow
18.1x
6.5x36.2x
72nd percentile, above its median of 12.7x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
108x
Earnings yield
0.9%
Price / sales
3.6x
Price / book
2.0x
Price / operating cash flow
16.7x
EV / EBITDA
26.6x
EV / sales
4.2x
Free cash flow yield
5.5%

Profitability

Gross margin
74.0%
Operating margin
n/a
Net margin
3.4%
Return on equity
1.8%
Return on capital
n/a

n/a: Not reported

Growth per year

Revenue, 3 years
-0.9%
Revenue, 5 years
-6.0%
Revenue, 9 years
-1.6%
EPS, 3 years
-25.0%

Balance sheet

Cash and investments
$1.30B
Total debt
$7.29B
Net cash
-$5.99B
Debt / equity
0.39x
Current ratio
1.95x

Shares and dividend

Shares outstanding
148M
Share count, 5 years
-8.8%
Beta, 1 year
0.37
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $2.80B
RevenueNet income
Gross profitLatest quarter $2.06B
EBITDALatest quarter $320M
Margins73 / 24 / -1%
GrossOperatingNet
Earnings per shareLatest quarter -$0.14
Cash flowLatest quarter $641M
OperatingCapexFree
Cash vs debtLatest quarter $1.30B
Cash and investmentsTotal debt
P/E historyNow 108x
P/E, median 17.0x dashed
P/S historyNow 3.6x
P/S, median 3.4x dashed

Where the revenue comes from

Rare Disease Product Revenue went from 18% to 22% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

Rare Disease Product RevenueTysabri ProductSPINRAZAFumarateInterferonVUMERITYOther
FY22
18%18%13%
$10.2B
FY23
19%18%16%11%9%
$9.84B
FY24
16%16%10%8%
$9.68B
FY25
22%17%16%14%10%15%
$9.89B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Rare Disease Product Revenue$2.15B21.8%n/a
Tysabri Product$1.67B16.8%n/a
SPINRAZA$1.55B15.6%-2%
Fumarate$1.43B14.4%-11%
Interferon$946M9.6%-2%
VUMERITY$747M7.6%n/a
Other$1.46B14.8%+84%

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
BIIB Biogen Inc. $37.5B +2% n/a108x3.6x Highest in its range

The company

Sector
Health Care
Industry
Biotechnology
CEO
Michel Vounatsos
Founded
1978
Headquarters
Cambridge, MA
Fiscal year ends
December
Website
biogen.com

What it does

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about BIIB.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 750 active funds. Crowd level: quiet.

Open the Smart money tab